Vaxart Inc (NASDAQ:VXRT)

5.90
Delayed Data
As of 4:00pm ET
 -0.29 / -4.68%
Today’s Change
4.74
Today|||52-Week Range
11.88
-5.29%
Year-to-Date
SECTOR
--
INDUSTRY
--
MARKET CAP
$21.8M

Company Description

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.

Contact Information

Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Alpharetta Georgia 30009
P:(678) 221-3343
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Joseph M. PattiPresident, CEO & Executive Director
Mark P. ColonneseChief Financial Officer & Executive Vice President
Anna Novotney-BarryVice President-Clinical Development
John H. VernachioVice President-Preclinical Development
Jonas NiauraVice President-Corporate Development & Strategy